114 related articles for article (PubMed ID: 26144261)
1. A potential tailor-made hyaluronic acid buccal delivery system comprising rotigotine for Parkinson's disease?
Laffleur F; Wagner J; Barthelmes J
Future Med Chem; 2015; 7(10):1225-32. PubMed ID: 26144261
[TBL] [Abstract][Full Text] [Related]
2. Transdermal rotigotine (Neupro) for Parkinson's disease.
Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291
[No Abstract] [Full Text] [Related]
3. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
Lyons KE; Pahwa R
Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
[TBL] [Abstract][Full Text] [Related]
4. Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system.
Lyons KE
Neurol Clin; 2013 Aug; 31(3 Suppl):vii-ix. PubMed ID: 23931955
[No Abstract] [Full Text] [Related]
5. The development of the rotigotine transdermal patch: a historical perspective.
Waters C
Neurol Clin; 2013 Aug; 31(3 Suppl):S37-50. PubMed ID: 23931953
[TBL] [Abstract][Full Text] [Related]
6. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
7. Permeation enhancement via thiolation: in vitro and ex vivo evaluation of hyaluronic acid-cysteine ethyl ester.
Laffleur F; Psenner J; Suchaoin W
J Pharm Sci; 2015 Jul; 104(7):2153-60. PubMed ID: 25900642
[TBL] [Abstract][Full Text] [Related]
8. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
[TBL] [Abstract][Full Text] [Related]
9. Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects.
Yan X; Xu L; Bi C; Duan D; Chu L; Yu X; Wu Z; Wang A; Sun K
Int J Nanomedicine; 2018; 13():273-281. PubMed ID: 29391788
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
11. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Ceballos-Baumann A; Häck HJ
Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
[TBL] [Abstract][Full Text] [Related]
12. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
[TBL] [Abstract][Full Text] [Related]
13. Rotigotine: Parkinson's disease: a step backward.
Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
[TBL] [Abstract][Full Text] [Related]
14. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
[TBL] [Abstract][Full Text] [Related]
15. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
Naidu Y; Chaudhuri KR
Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
[TBL] [Abstract][Full Text] [Related]
16. In vitro and ex vivo evaluation of biomaterials' distinctive properties as a result of thiolation.
Laffleur F; Wagner J; Mahmood A
Future Med Chem; 2015; 7(4):449-57. PubMed ID: 25875872
[TBL] [Abstract][Full Text] [Related]
17. Chemical modification of hyaluronic acid for intraoral application.
Laffleur F; Röggla J; Idrees MA; Griessinger J
J Pharm Sci; 2014 Aug; 103(8):2414-23. PubMed ID: 24985030
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of modified hyaluronic acid in terms of rheology, enzymatic degradation and mucoadhesion.
Laffleur F; Netsomboon K; Erman L; Partenhauser A
Int J Biol Macromol; 2019 Feb; 123():1204-1210. PubMed ID: 30465836
[TBL] [Abstract][Full Text] [Related]
19. Effects of rotigotine and rotigotine extended-release microsphere therapy on myocardial ischemic injury in mice.
Lv H; Yu F; Sha C; Huang Y; Lu Y; Zhang L; Zhai R; Wang T; Fu F
Eur J Pharm Sci; 2019 Jun; 134():1-6. PubMed ID: 30959104
[TBL] [Abstract][Full Text] [Related]
20. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Bhattamisra SK; Shak AT; Xi LW; Safian NH; Choudhury H; Lim WM; Shahzad N; Alhakamy NA; Anwer MK; Radhakrishnan AK; Md S
Int J Pharm; 2020 Apr; 579():119148. PubMed ID: 32084576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
